Clinical Trial Update: A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial assessing BMS-986207 with nivolumab and ipilimumab as first-line treatment for stage IV non-small cell lung cancer has completed with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• BMS-986207
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2024-02-28